Teniposide (VM26) disposition in children with leukemia

Area of Science:

• Pharmacology
• Oncology
• Pediatrics

Background:

• Teniposide (VM-26) is an anticancer drug used in treating acute lymphocytic leukemia (ALL).
• Understanding its clinical pharmacokinetics is crucial for optimizing treatment and minimizing toxicity in pediatric patients.
• Previous studies have explored teniposide's disposition, but further investigation into influencing factors is warranted.

Purpose of the Study:

• To characterize the clinical pharmacokinetics of teniposide in pediatric patients with ALL.
• To identify patient-specific factors that influence teniposide's systemic clearance, elimination rate, and area under the concentration-time curve (AUC).
• To establish mathematical models correlating demographic and laboratory values with pharmacokinetic parameters.

Main Methods:

• Pharmacokinetic analysis of teniposide in 21 children with ALL receiving a standard dose (165 mg/sq m).
• Plasma samples analyzed using high-performance liquid chromatography with electrochemical detection.
• Both compartmental and non-compartmental pharmacokinetic models were applied.
• Regression analyses (univariate and multivariate) were used to correlate patient data with pharmacokinetic parameters.

Main Results:

• Systemic clearance averaged 13.82 +/- 6.0 ml/min/sq m and steady-state volume of distribution was 7.9 +/- 4.0 liter/sq m.
• A significant correlation was observed between serum alkaline phosphatase levels and systemic clearance, elimination rate constant, and AUC.
• These findings suggest that liver function plays a role in teniposide disposition.

Conclusions:

• Serum alkaline phosphatase is a significant predictor of teniposide pharmacokinetics in children with ALL.
• Liver function influences the systemic clearance and overall exposure to teniposide.
• These insights can aid in tailoring teniposide dosing strategies for pediatric ALL patients to improve therapeutic outcomes.